Loading...
Loading...
ABCL| Name | Value |
|---|---|
| Revenues | 12.2M |
| Cost of Revenue | 52.6M |
| Gross Profit | -40.5M |
| Operating Expense | 73.7M |
| Operating I/L | -61.5M |
| Other Income/Expense | 16.7M |
| Interest Income | 9.8M |
| Pretax | -48.1M |
| Income Tax Expense | -8.0M |
| Net Income/Loss | -40.1M |
AbCellera Biologics Inc. operates an artificial intelligence-powered antibody discovery platform, analyzing natural immune system databases to identify potential drug antibodies. The company has 156 discovery programs in progress or under contract with 36 partners, generating revenue through research collaborations and license agreements. Its partnership with Eli Lilly and Company further enhances its revenue streams.
